Artiva Biotherapeutics, Inc. 4

Artiva Biotherapeutics’ Chief Tech Operations Officer Christopher Horan received 40,000 RSUs and stock options for 120,000 shares at $10.79 as equity compensation, raising his direct holdings to 323,084 shares plus 120,000 options.

On September 9, 2026, Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., received an equity compensation package consisting of 40,000 shares of common stock in the form of restricted stock units and an employee stock option for 120,000 shares exercisable at $10.79 per share, with the option scheduled to vest in equal monthly installments over four years beginning September 8, 2026. These awards, granted under the issuer's 2024 Equity Incentive Plan, are non‑cash, service-based compensation and increase Horan’s direct beneficial ownership to 323,084 shares of common stock and 120,000 option shares. The vesting structure links the realization of value to continued employment, and no open‑market purchases or sales were reported in this filing.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-389512

Alert Tier

5